Osmind

Challenger

SF YC W20 psychiatric EHR for ketamine/psychedelic/TMS treatment practices; $55.2M total ($40M DFJ/General Catalyst/Tiger Series B May 2022) competing with Valant for emerging mental health treatment specialty EHR.

Updated March 2026

Company Overview

About Osmind

Osmind is a San Francisco-based psychiatry and mental health EHR (electronic health record) platform — backed by Y Combinator (W20) with $55.2 million in total funding including a $40 million Series B in May 2022 led by DFJ Growth with General Catalyst, Future Ventures, Tiger Global, Susa Ventures, Lachy Groom, and Pear VC — providing psychiatric practices with research-grade EHR technology specialized for emerging mental health treatments including ketamine therapy, psychedelic-assisted psychotherapy (psilocybin, MDMA), transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT). Founded in 2020, Osmind captures clinical data during novel psychiatric interventions in structured formats that enable both optimized patient care workflows and real-world evidence research — serving the growing segment of psychiatric practices offering treatment-resistant depression interventions.

Business Model & Competitive Advantage

Osmind's specialized psychiatric EHR addresses the workflow and research data gap at the intersection of psychiatry and emerging treatments: general-purpose EHRs (Epic, Athenahealth) capture clinical notes and prescriptions but don't have the structured data fields for ketamine infusion parameters, psychedelic session dosing and set/setting documentation, or TMS treatment course tracking — forcing psychiatrists offering these treatments to use paper forms, Google Docs, or workarounds that neither optimize clinical workflow nor produce the research-quality data that these novel treatments require for outcomes evidence generation. Osmind's platform (purpose-built for the clinical workflow of ketamine and psychedelic-assisted treatment sessions, with structured intake assessments, session documentation forms, and outcome measure tracking using validated psychiatric scales like PHQ-9 and the Mystical Experience Questionnaire) provides both practice efficiency and the clinical database that supports evidence generation.

Competitive Landscape 2025–2026

In 2025, Osmind competes in the psychiatric EHR, behavioral health technology, and mental health practice management market with Blueprint (behavioral health EHR, $10M raised), Valant (behavioral health EHR, $45M raised), and Epic (dominant EHR, private, $5B+ revenue) for psychiatric practice and ketamine/psychedelic treatment clinic EHR and practice management platform adoption. DFJ Growth's Series B leadership and General Catalyst's participation reflect healthtech infrastructure conviction. Tiger Global's investment provides growth equity backing for market expansion. Y Combinator W20 connects Osmind with the digital health investment community. The 2025 strategy focuses on growing the ketamine and psychedelic clinic segment (rapidly expanding as treatments gain clinical acceptance), building the real-world evidence database for psychiatric treatment outcomes, and expanding the research network for clinical trials using Osmind's structured data for novel psychiatric treatment investigation.

Revenue
$55.2M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Strong Challenger

Osmind is an established challenger with significant market presence and competitive offerings in Healthcare.

Frequently Asked Questions

Not So Random Others

AbbVie

Healthcare
AnalyticsB2bEnterpriseGlobalHealthtechPublic

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp

Adni

Healthcare
HealthtechSaasGlobal

Adni is a Singapore-headquartered AI-powered super app for healthcare workers — backed by Y Combinator with $1.38 million raised including a $1.25 million seed round in May 2022 from YC, Flare Capital

Quantinuum

Technology
B2bGlobalHardwareInfrastructureQuantum

Quantinuum is a Cambridge, UK and Broomfield, Colorado-based integrated quantum computing company — majority owned by Honeywell (NASDAQ: HON) with $625+ million in total funding including a $300 milli

H&M (Hennes & Mauritz)

retail
B2cRetailtechPublicGlobalEurope

H&M Hennes & Mauritz is a Swedish multinational fashion retailer founded in 1947, operating brands including H&M, COS, & Other Stories, ARKET, and Weekday. The company runs approximately 4,100 stores

Scaleway

AI Infrastructure
B2bPlatformCloud NativeInfrastructureGlobalDeveloper Tools

Scaleway is a French cloud computing provider and subsidiary of Iliad Group, the telecommunications and technology conglomerate founded by billionaire Xavier Niel. Originally launched as Online.net in

Yoneda Labs

Healthcare
HealthtechB2bNorth America

Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit

Compare Osmind with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Osmind

Claim This Profile

Are you from Osmind? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Osmind Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Osmind vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →